Consideration of use of neuraminidase inhibitors such as oseltamivir and zanamivir in IgA nephropathy  by Altschuler, Eric Lewin et al.
2910 Letters to the Editor
which changed slightly. More important, for a reasonable
interpretation of our findings, we have proceeded to do a
formal comparison of liver weight after normalization for
total body weight, using analysis of variance (ANOVA).
This analysis showed not only a significant group effect
that is lower body weights in CRF versus no CRF groups
(P < 0.001), but also a significant treatment effect that is
lower body weights in lanthanum versus no lanthanum
treatment (P < 0.022), with no interaction. In addition,
ANOVA also showed significant effects of both group
and treatment on liver weight (P < 0.001 and <0.001),
and heart weight (p < 0.001 and <0.017). In contrast,
although there was a significant group effect on brain,
lung, and femur weight (P < 0.001), there was no lan-
thanum treatment effect on the weight of these two tis-
sues. When normalizing the organ weights for total body
weight, ANOVA showed significant effects of both group
and treatment on liver weight (P < 0.038 and < 0.004),
brain weight (P < 0.001 and <0.009), and femur weight
(P < 0.001 and <0.047), whereas only group effects were
seen for heart and lung weights (both P < 0.001).
The results of these ANOVAs confirm our previous
observations of a deleterious effect of prolonged admin-
istration of high amounts of lanthanum carbonate on liver
weight, as shown in Table 1 of our study [1], using post-
hoc tests to make comparisons easily understandable, and
extends them to total body weight and that of other or-
gans. This demonstrates that the rough analysis made by
Rambeck (see Table) based on body weights approxi-
mated from Figure 1 of our article led him to reach an
erroneous conclusion. Because he did not have access
to individual values for the calculation of possible group
effects, we wonder how he could claim that the signifi-
cant effects of lanthanum administration on liver weight
disappeared after correction of organ weights for body
weight.
Concerning Rambeck’s remark on quantitative (not
qualitative) differences in tissue lanthanum deposition
between rat groups we would like to offer the following
answers. (1) Lanthanum content in renal tissue has been
expressed per g dry weight, as it has been for all other
tissues examined. Expressed in this way, lanthanum con-
tent is significantly higher in kidneys from lanthanum-
overloaded CRF rats after subtotal nephrectomy (Nx)
than in kidneys from lanthanum-overloaded CRF rats
after exposure to adenine (see Fig. 4F of our paper [1]).
However, considering the fact that the mean weight of
the remaining renal tissue after bipolar left Nx and con-
tralateral total Nx in lanthanum-overloaded rats was only
727 mg (fresh wet weight), as compared to a mean to-
tal renal tissue mass of 2092 mg (fresh wet weight) in
adenine-treated rats with lanthanum overload, the actual
total mean amount of lanthanum accumulated in renal tis-
sue was roughly the same between the two groups, namely
29.5 ng per total kidney mass (wet weight) in Nx rats and
27.9 ng per total kidney mass (wet weight) in adenine-
treated rats. (2) The extremely high plasma lanthanum
concentrations in all rats groups are due to a regrettable
error in the units used (see detailed explanation above
given to McLeod et al). (3) We have no easy explanation
for the variations of lanthanum concentrations observed
in different tissues between rats with normal renal func-
tion and CRF rats, and between the two different CRF
models used, except the 3 to 30 times greater accumu-
lation in the liver than in the other organs. Because the
liver is the first organ exposed to lanthanum after its in-
testinal absorption, and because mean liver lanthanum
concentrations were above 1200 ng/g dry weight in the
two CRF models, in contrast to mean lanthanum concen-
trations below 400 ng/g dry weight in all other organs,
it is reasonable to assume that the liver performed its
usual function of trapping absorbed compounds during
first passage. Alternatively, one could also hypothesize a
possible role of adenine overload in favoring lanthanum
absorption and/or tissue deposition and retention. How-
ever, we failed to observe a specific adenine treatment
effect.
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Consideration of use of
neuraminidase inhibitors such
as oseltamivir and zanamivir in
IgA nephropathy
To the Editor: IgA nephropathy (IgAN) is the most
common glomerulonephritis worldwide. Nonspecific
treatments such as steroids are unfortunately often not
particularly efficacious in IgAN and, as the pathogene-
sis of the disease has remained obscure, specific treat-
ment has been lacking. Recently, Xu and Zhao [1] have
found aberrantly glycosylated serum IgA1 in IgAN. In
particular, they find that the IgA1 in IgAN patients with
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the more severe histologic subtypes of focal prolifera-
tive and sclerosing disease has reduced O-linked sialic
acid and galactosylation than samples from normal con-
trols, and that all groups of IgAN patients have increased
exposure of N-acetylgalactosamine residues in their IgA1
compared with normal controls. This work is consistent
with previous work that also found decreased sialation
in IgAN patients (see e.g., [2] and others therein). The
decreased sialation may be fundamental in the patho-
genesis of IgAN as desialation may further expose IgA1
to degalactosylation. Such aberrantly glycosalted IgA1
may be important in the pathogenesis of IgAN because
it may be deposited in the mesangium. Whether funda-
mental to the pathogenesis or not, we just want to note
that desialation may be a useful point at which to inter-
vene for therapy for IgAN. It may be possible to screen
for and design medicinals that specifically block the de-
sialation of IgA1 without unacceptable side effects. We
further note that there is at least a small possibility that
a useful sialation inhibitor not only already exists, but
is also approved for use worldwide. Indeed, neuraminic
acid is a synonym for sialic acid. Two neuraminidase
inhibitors—oseltamivir and zanamivir—are currently li-
censed and in use worldwide for treatment and imme-
diate prophylaxis for influenza virus infection [3]. While
designed to work against the viral neuraminidase, there is
at least some evidence that these medicines are also active
against a mammalian neuraminidase [4]. Neuraminidase
inhibitors—oseltamivir and zanamivir or others—would
be a much needed addition to the treatment armamen-
tarium for IgAN and are worthy of further consideration
and potential study.
ERIC LEWIN ALTSCHULER, AJAY BHATIA, and RICHARD E. KAST
Newark, New Jersey, Bronx, New York, and Burlington, Vermont
Correspondence to Eric Lewin Altschuler, University of Medicine &
Dentistry of New Jersey, 30 Bergen Street, ADMC 1, Suite 101, Newark,
NJ 07101.
E-mail: eric.altschuler@umdnj.edu
and
Richard E. Kast, University of Vermont, 2 Church Street, Burlington,
VT 05401.
E-mail: rekast@email.com
REFERENCES
1. XU L-X, ZHAO M-H: Aberrantly glycosylated serum IgA1 are closely
associated with pathologic phenotypes of IgA nephropathy. Kidney
Int 68:167–172, 2005
2. COPPO R, AMORE A: Aberrant glycosylation in IgA nephropathy
(IgAN). Kidney Int 65:1544–1547, 2005
3. NICHOLSON KG, WOOD JM, ZAMBON M: Influenza. Lancet 362:1733–
1745, 2003
4. CRAIN SM, SHEN KF: Neuraminidase inhibitor, oseltamivir blocks
GM1 ganglioside-regulated excitatory opioid receptor-mediated hy-
peralgesia, enhances opioid analgesia and attenuates tolerance in
mice. Brain Research 995:260–266, 2004
Thrombocytopenia induced by
nicotinamide in hemodialysis
patients
To the Editor: Recently, Takahashi [1] proposed in
an article in Kidney International the prescription of
nicotinamide in order to control phosphorus level in
hemodialysis patients. Nicotinamide is a circulating form
of nicotinic acid. It was suggested that nicotinamide is
probably an effective inhibitor of phosphorus absorp-
tion in the intestine. Serum phosphorus level decreased
in the study in 65 hemodialysis patients from 2.23 ±
0.48 mmol/L to 1.74 ± 0.42 mmol/L after 12 weeks
of treatment. The authors concluded that nicotinamide
may provide an alternative for controlling hyperphos-
phatemia in hemodialysis patients.
In our dialysis unit, where we treat 100 patients, the
control of phosphoremia is essentially obtained by diet
and prescription of sevelamer [2]. Mean phosphorus level
during the last 6 months was 1.77 ± 0.36 mmol/L. Nev-
ertheless, some patients did not reach this level. We
prescribed nicotinamide in 6 of them at a dosage of
1000 mg/day. Because a transitory decline in platelet
count was described in 1 out 65 patients in the Japanese
study, we controlled the platelet count every 2 weeks.
In 1 patient the platelet count remained stable, but in 5
of them we observed a dramatic decrease in the platelet
count within 3 months of prescription.
Data are expressed as mean ± standart deviation in lL,
and a P value of less than 0.05 was considered statistically
significant. The mean platelet count 3 months before the
prescription of nicotinamide was 188,000 ± 17,000. The
mean platelet count during the 3 months of prescription
was 122,000 ± 41,000 (P < 0.001). Ten days after discon-
tinuation of the drug the mean platelet count increased to
150,000 ± 9100 (P < 0.01). For each patient, the throm-
bocytopenia was significant (P < 0.001). We looked at
the overall prescriptions of our 6 patients: the only one in
common was the prescription of sevelamer, which is not
described as inducing a thrombocytopenia. Nicotinamide
has been given over the past 40 years at high doses for a
variety of therapeutic applications [3]. Nicotinic acid and
its derivatives were seldom reported to induce thrombo-
cytopenia [4, 5]. The mechanism of this side effect has
not been completely elucidated to date: thrombocytope-
nia may result from decreased levels of thyroxin-binding
globulin induced by nicotinic acid or one of its deriva-
tives. We suggest to control very carefully the prescrip-
tion of nicotinamide in patients undergoing hemodialysis,
and probably to insist more on diet prescription than on
drugs to control hyperphosphatemia.
